Compare Merck & Co., Inc. (MRK) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while State Street SPDR S&P Homebuilders ETF trades at $99.14. The key difference: Merck & Co., Inc. pays a 2.29% dividend while State Street SPDR S&P Homebuilders ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| MRK | XHB | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $121.36 |
52-Week Low | $77.60 | $94.86 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
XHB trades at $100.75, down 2.42% today amid bearish technical signals. The ETF shows neutral oscillators but bearish moving averages, with support at $98-$100 and resistance at $102-$105. Recent housing data shows mixed signals with new home sales rising 1.6% in June (Census Bureau, June 2026) while existing home sales declined 2.4% (WSJ, July 9, 2026).
The homebuilding sector faces headwinds from high mortgage rates and record home prices, though institutional interest remains with Greenland Capital's $17.33 million investment (Defense World, September 7, 2026). Key catalysts include housing affordability legislation and potential market rebound opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
